DexCom Inc. (DXCM): Price and Financial Metrics

DexCom Inc. (DXCM): $133.56

1.16 (-0.86%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

A

DXCM Price/Volume Stats

Current price $133.56 52-week high $139.55
Prev. close $134.72 52-week low $74.75
Day low $131.65 Volume 104,497
Day high $134.32 Avg. volume 3,161,662
50-day MA $124.39 Dividend yield N/A
200-day MA $113.84 Market Cap 51.49B

DXCM Stock Price Chart Interactive Chart >

DXCM POWR Grades

  • DXCM scores best on the Quality dimension, with a Quality rank ahead of 91.95% of US stocks.
  • The strongest trend for DXCM is in Stability, which has been heading down over the past 26 weeks.
  • DXCM ranks lowest in Momentum; there it ranks in the 7th percentile.

DXCM Stock Summary

  • DXCM has a market capitalization of $46,469,193,162 -- more than approximately 94.56% of US stocks.
  • With a price/earnings ratio of 123.26, DEXCOM INC P/E ratio is greater than that of about 95.06% of stocks in our set with positive earnings.
  • The price/operating cash flow metric for DEXCOM INC is higher than 94.96% of stocks in our set with a positive cash flow.
  • If you're looking for stocks that are quantitatively similar to DEXCOM INC, a group of peers worth examining would be PODD, DT, FICO, NABL, and ESMT.
  • Visit DXCM's SEC page to see the company's official filings. To visit the company's web site, go to www.dexcom.com.

DXCM Valuation Summary

  • In comparison to the median Healthcare stock, DXCM's price/sales ratio is 540.91% higher, now standing at 14.1.
  • DXCM's price/earnings ratio has moved up 145.4 over the prior 228 months.

Below are key valuation metrics over time for DXCM.

Stock Date P/S P/B P/E EV/EBIT
DXCM 2023-12-29 14.1 21.1 127.2 86.4
DXCM 2023-12-28 14.1 21.2 127.2 86.5
DXCM 2023-12-27 14.0 21.1 126.8 86.2
DXCM 2023-12-26 14.0 21.0 126.6 86.0
DXCM 2023-12-22 13.9 20.8 125.2 85.1
DXCM 2023-12-21 13.9 20.9 125.9 85.5

DXCM Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at 263.1%.
  • Its 3 year net cashflow from operations growth rate is now at 238%.
  • The 2 year net cashflow from operations growth rate now stands at 59.46%.
Over the past 15 months, DXCM's revenue has gone up $590,600,000.

The table below shows DXCM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 2,909.8 669.5 341.2
2022-09-30 2,792.8 642.8 230
2022-06-30 2,673.4 596.9 199.7
2022-03-31 2,572.3 485.7 211.7
2021-12-31 2,448.5 442.5 154.7
2021-09-30 2,319.2 508.7 529.3

DXCM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DXCM has a Quality Grade of B, ranking ahead of 87.89% of graded US stocks.
  • DXCM's asset turnover comes in at 0.517 -- ranking 89th of 186 Medical Equipment stocks.
  • VRAY, ZYXI, and SRTS are the stocks whose asset turnover ratios are most correlated with DXCM.

The table below shows DXCM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.517 0.693 0.081
2021-06-30 0.510 0.692 0.077
2021-03-31 0.506 0.675 0.070
2020-12-31 0.547 0.664 0.077
2020-09-30 0.597 0.654 0.089
2020-06-30 0.651 0.639 0.090

DXCM Price Target

For more insight on analysts targets of DXCM, see our DXCM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $530.60 Average Broker Recommendation 1.36 (Strong Buy)

DexCom Inc. (DXCM) Company Bio


Dexcom was founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston and Bret Megargel. In 2006, Dexcom received U.S. Food and Drug Administration (FDA) approval and launched the Dexcom STS Continuous Glucose Monitoring System, which is a three-day sensor that provides up to 288 glucose measurements for every 24 hours. Dexcom received approval of the second generation product, the Seven Continuous Glucose Monitoring System in May 2007. This device improved on accuracy and extended use from three to seven days. In 2008, Dexcom announced two consumer development agreements with Insulet Corporation and Animas Corporation as well as a development agreement with Edwards Lifesciences for a continuous glucose monitor in the intensive care unit hospital environment. (Source:Wikipedia)


DXCM Latest News Stream


Event/Time News Detail
Loading, please wait...

DXCM Latest Social Stream


Loading social stream, please wait...

View Full DXCM Social Stream

Latest DXCM News From Around the Web

Below are the latest news stories about DEXCOM INC that investors may wish to consider to help them evaluate DXCM as an investment opportunity.

3 Medical-Device Stocks Could Click in 2024

Baird is bullish on Boston Scientific, Insulet, and DexCom, stocks set to benefit as those companies ramp up sales.

Yahoo | December 26, 2023

5 MedTech Stocks Poised to Continue Their Winning Streaks in 2024

Stocks like DexCom Inc. (DXCM), Integer Holdings (ITGR), Penumbra (PEN), Haemonetics (HAE), Health Equity (HAE) and are likely to continue their strong performance in 2024.

Yahoo | December 26, 2023

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Key Insights Using the 2 Stage Free Cash Flow to Equity, DexCom fair value estimate is US$117 Current share price of...

Yahoo | December 26, 2023

DexCom (DXCM) Stock Falls Amid Market Uptick: What Investors Need to Know

In the closing of the recent trading day, DexCom (DXCM) stood at $122.17, denoting a -0.51% change from the preceding trading day.

Yahoo | December 22, 2023

3 Reasons Why Growth Investors Shouldn't Overlook DexCom (DXCM)

DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Yahoo | December 22, 2023

Read More 'DXCM' Stories Here

DXCM Price Returns

1-mo 14.11%
3-mo 14.51%
6-mo 49.93%
1-year 13.95%
3-year 55.02%
5-year 275.80%
YTD 7.63%
2023 9.58%
2022 -15.64%
2021 45.23%
2020 69.02%
2019 82.59%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!